STK26

Across TCGA pan-cancer cohorts, STK26 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STK26 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher STK26 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STK26 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where STK26 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.235	0.887	.005	43	view →
PDAC	OS	Median	III,IV	0.605	0.889	.037	5	view →
LUAD	DFS	Quartile	II,III,IV	0.368	0.717	.022	4	view →
LSCC	DFS	Median	II,III,IV	0.800	0.552	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STK26–CCRCC (DFS)

Open the CCRCC breakdown →